Novo Nordisk A/S-Product Pipeline Review-2016

Novo Nordisk A/S-Product Pipeline Review-2016

  • Products Id :- GMDHC07988CDB
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Novo Nordisk A/S-Product Pipeline Review-2016', provides an overview of the Novo Nordisk A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novo Nordisk A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the pipeline therapeutic landscape of Novo Nordisk A/S

The report provides overview of Novo Nordisk A/S including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Novo Nordisk A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Novo Nordisk A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate Novo Nordisk A/S's strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Novo Nordisk A/S

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Novo Nordisk A/S's pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Novo Nordisk A/S Snapshot 7

Novo Nordisk A/S Overview 7

Key Information 7

Key Facts 7

Novo Nordisk A/S-Research and Development Overview 8

Key Therapeutic Areas 8

Novo Nordisk A/S-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Combination Treatment Modalities 13

Pipeline Products-Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Novo Nordisk A/S-Pipeline Products Glance 16

Novo Nordisk A/S-Late Stage Pipeline Products 16

Pre-Registration Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

Novo Nordisk A/S-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Novo Nordisk A/S-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Novo Nordisk A/S-Drug Profiles 21

(insulin aspart + insulin degludec) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

(insulin degludec + liraglutide) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

insulin degludec 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

NN-1218 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

nonacog beta pegol 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

NN-9535 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

somapacitan 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

turoctocog alfa pegol 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

liraglutide (recombinant) 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

liraglutide (recombinant) + NN-8828 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

NN-9536 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

NN-9709 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

OG-217SC 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

OI-338GT 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

AM-833 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

concizumab 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

G-530L 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

LAI-287 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

NN-1406 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

NN-9747 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

NN-9748 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

OI-320GT 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Insulin 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Synthetic Peptides to Agonize NMUR1 and NMUR2 for Obesity and Diabetes 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

XMet-A 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Novo Nordisk A/S-Pipeline Analysis 58

Novo Nordisk A/S-Pipeline Products by Target 58

Novo Nordisk A/S-Pipeline Products by Route of Administration 60

Novo Nordisk A/S-Pipeline Products by Molecule Type 61

Novo Nordisk A/S-Pipeline Products by Mechanism of Action 62

Novo Nordisk A/S-Recent Pipeline Updates 63

Novo Nordisk A/S-Discontinued Pipeline Products 85

Discontinued Pipeline Product Profiles 85

balaglitazone 85

coagulation factor XIII A-subunit (recombinant) 85

LAI-338 86

liraglutide (recombinant) 86

NN-1952 86

NN-1954 86

NN-1955 86

NN-1956 86

NN-1998 87

NN-7128 87

NN-7129 87

NN-8555 87

NN-8828 87

NN-9112 87

NN-9161 87

NN-9925 87

NNC126-0083 87

OG-217GT 88

OG-987GT 88

OG-987SC 88

ragaglitazar 88

semaglutide 88

tifenazoxide 88

vatreptacog alfa (activated) 88

Novo Nordisk A/S-Company Statement 89

Novo Nordisk A/S-Locations And Subsidiaries 91

Head Office 91

Other Locations & Subsidiaries 91

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

List of Figures

Novo Nordisk A/S-Pipeline by Indication, 2016 9

Novo Nordisk A/S-Pipeline by Stage of Development, 2016 11

Novo Nordisk A/S-Monotherapy Products in Pipeline, 2016 12

Novo Nordisk A/S-Combination Treatment Modalities in Pipeline, 2016 13

Novo Nordisk A/S-Partnered Products in Pipeline, 2016 14

Novo Nordisk A/S-Pipeline by Top 10 Target, 2016 58

Novo Nordisk A/S-Pipeline by Route of Administration, 2016 60

Novo Nordisk A/S-Pipeline by Molecule Type, 2016 61

Novo Nordisk A/S-Pipeline Products by Top 10 Mechanism of Action, 2016 62

List of Tables

Novo Nordisk A/S, Key Information 7

Novo Nordisk A/S, Key Facts 7

Novo Nordisk A/S-Pipeline by Indication, 2016 9

Novo Nordisk A/S-Pipeline by Stage of Development, 2016 11

Novo Nordisk A/S-Monotherapy Products in Pipeline, 2016 12

Novo Nordisk A/S-Combination Treatment Modalities in Pipeline, 2016 13

Novo Nordisk A/S-Partnered Products in Pipeline, 2016 14

Novo Nordisk A/S-Partnered Products/ Combination Treatment Modalities, 2016 15

Novo Nordisk A/S-Pre-Registration, 2016 16

Novo Nordisk A/S-Phase III, 2016 17

Novo Nordisk A/S-Phase II, 2016 18

Novo Nordisk A/S-Phase I, 2016 19

Novo Nordisk A/S-Preclinical, 2016 20

Novo Nordisk A/S-Pipeline by Target, 2016 58

Novo Nordisk A/S-Pipeline by Route of Administration, 2016 60

Novo Nordisk A/S-Pipeline by Molecule Type, 2016 61

Novo Nordisk A/S-Pipeline Products by Mechanism of Action, 2016 62

Novo Nordisk A/S-Recent Pipeline Updates, 2016 63

Novo Nordisk A/S-Discontinued Pipeline Products, 2016 85

Novo Nordisk A/S, Subsidiaries 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Novo Nordisk A/S; Novo Nordisk A/S - Key Therapeutics; Novo Nordisk A/S - Pipeline Overview and Promising Molecules; Novo Nordisk A/S - News; Novo Nordisk A/S - Latest Updates; Novo Nordisk A/S - Pipeline; Novo Nordisk A/S - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 108615
Site License
USD 3000 INR 217230
Corporate User License
USD 4500 INR 325845



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]